TY - JOUR
T1 - The effect of the acute phase of infection on absorption of and exposure to orally administered antibiotics in non-critically ill, hospitalized patients
AU - van den Broek, A. K.
AU - Visser, C. E.
AU - Veenstra, J.
AU - van den Berg, B. T. J.
AU - Prins, J. M.
AU - van Hest, R. M.
N1 - Funding Information: We thank the patients who were willing to participate to this study, all the staff of the general wards of the participating hospitals for contributing to the study, and Marcel Pistorius, Dennis van der Laan and colleagues from the Laboratory of Clinical Pharmacology of the Amsterdam UMC for the amoxicillin and ciprofloxacin concentration measurements. We also thank Tingjie Guo, Assistant Professor of Pharmacometrics, Leiden Amsterdam Centre for Drug Research, Leiden University, for his guidance on NONMEM. This work was funded by the Amsterdam UMC, University of Amsterdam. Funding Information: This work was funded by the Amsterdam UMC, University of Amsterdam. Publisher Copyright: © The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
PY - 2023/2/1
Y1 - 2023/2/1
N2 - Objectives: During the acute phase of infection, IV antibiotics are preferred to ensure adequate systemic exposure. To assess whether adequate exposure may also be achieved with oral antibiotics, we investigated exposure to oral antibiotics and PTA during the acute phase of infection and after defervescence. Methods: We enrolled hospitalized, non-critically ill febrile patients treated with IV antibiotics other than amoxicillin or ciprofloxacin. The study consisted of two visits: when patients had received <24 h IV treatment; and when patients had become afebrile. On both visits, patients received one additional dose of 750 mg amoxicillin, or 500 mg ciprofloxacin, depending on the presumed infection, after which serial blood samples were obtained. The primary endpoint was the ratio of the AUC during the febrile and the afebrile phase. The AUCs were considered to be equivalent when the ratio of the mean AUCs and its 90% CI was contained within the acceptance interval of 80%–125%. The secondary endpoint was PTA. Results: Forty-four patients (15 amoxicillin, 29 ciprofloxacin) completed both study visits. The median time between the two study visits was 65.8 h (range 33.8–427.4). The ratio of the mean AUCs (study visit 1/study visit 2) was 97% (90% CI of 80%–117%) for amoxicillin and 112% (90% CI of 108%–116%) for ciprofloxacin. The PTA for amoxicillin and ciprofloxacin did not differ between the two phases and was adequate to treat common pathogens. Conclusions: The acute phase of infection in non-critically ill febrile patients does not influence the exposure to, or PTA of, orally administered amoxicillin and ciprofloxacin. This might justify earlier IV-to-oral switching.
AB - Objectives: During the acute phase of infection, IV antibiotics are preferred to ensure adequate systemic exposure. To assess whether adequate exposure may also be achieved with oral antibiotics, we investigated exposure to oral antibiotics and PTA during the acute phase of infection and after defervescence. Methods: We enrolled hospitalized, non-critically ill febrile patients treated with IV antibiotics other than amoxicillin or ciprofloxacin. The study consisted of two visits: when patients had received <24 h IV treatment; and when patients had become afebrile. On both visits, patients received one additional dose of 750 mg amoxicillin, or 500 mg ciprofloxacin, depending on the presumed infection, after which serial blood samples were obtained. The primary endpoint was the ratio of the AUC during the febrile and the afebrile phase. The AUCs were considered to be equivalent when the ratio of the mean AUCs and its 90% CI was contained within the acceptance interval of 80%–125%. The secondary endpoint was PTA. Results: Forty-four patients (15 amoxicillin, 29 ciprofloxacin) completed both study visits. The median time between the two study visits was 65.8 h (range 33.8–427.4). The ratio of the mean AUCs (study visit 1/study visit 2) was 97% (90% CI of 80%–117%) for amoxicillin and 112% (90% CI of 108%–116%) for ciprofloxacin. The PTA for amoxicillin and ciprofloxacin did not differ between the two phases and was adequate to treat common pathogens. Conclusions: The acute phase of infection in non-critically ill febrile patients does not influence the exposure to, or PTA of, orally administered amoxicillin and ciprofloxacin. This might justify earlier IV-to-oral switching.
UR - http://www.scopus.com/inward/record.url?scp=85160665506&partnerID=8YFLogxK
U2 - https://doi.org/10.1093/jac/dkac401
DO - https://doi.org/10.1093/jac/dkac401
M3 - Article
C2 - 36433818
SN - 0305-7453
VL - 78
SP - 389
EP - 396
JO - The Journal of antimicrobial chemotherapy
JF - The Journal of antimicrobial chemotherapy
IS - 2
ER -